Nuechterlein Carole
- SEC CIK
- 0001665133
Latest role at each company
- ALGS Aligos Therapeutics, Inc.Directoras of Jun 29, 2026
- TRDA Entrada Therapeutics, Inc.Directoras of Jun 6, 2022
Trades
Every Form 4 that lists Nuechterlein Carole as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| ALGSAligos Therapeutics, Inc. | Oct 27, 20234:15 PM ET | Oct 25, 2023 | Nuechterlein CaroleDirector, 10% Owner | PPurchaseCommon Stock | +7.93M | $0.7568 | +$6M | 11.03M | +256.6% | SEC |
| ALGSAligos Therapeutics, Inc. | Oct 27, 20234:15 PM ET | Oct 25, 2023 | Nuechterlein CaroleDirector, 10% Owner | PPurchaseCommon Stock · Derivative | +3.97M | $0.125 | +$495.85K | 3.97M | – | SEC |